Novavax’s Pending EUA Likely Less Important Than Future Updates

Upcoming booster, adolescent data may be more commercially significant for the vaccine, which would enter a US market with few willing adults still unvaccinated. The tough prospects for one of the first COVID vaccines in development is a lesson in the importance of avoiding regulatory delays.

COVID-19 injection
Data on booster shots for Novavax's COVID-19 vaccine already has been submitted, the FDA said. • Source: Shutterstock

More from Vaccines

More from Pink Sheet